Headlines about Boston Scientific (NYSE:BSX) have trended somewhat positive this week, according to Accern Sentiment Analysis. The research group ranks the sentiment of media coverage by monitoring more than twenty million news and blog sources. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Boston Scientific earned a news impact score of 0.21 on Accern’s scale. Accern also assigned news headlines about the medical equipment provider an impact score of 45.5219861695266 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the near future.

These are some of the headlines that may have impacted Accern’s rankings:

Boston Scientific (NYSE:BSX) remained flat at $$25.78 during trading hours on Tuesday. 8,356,700 shares of the company’s stock traded hands, compared to its average volume of 7,088,286. The company has a debt-to-equity ratio of 0.58, a quick ratio of 0.50 and a current ratio of 0.72. Boston Scientific has a 12 month low of $21.32 and a 12 month high of $29.93. The company has a market capitalization of $35,401.00, a P/E ratio of 21.13, a price-to-earnings-growth ratio of 1.99 and a beta of 0.96.

Boston Scientific (NYSE:BSX) last released its quarterly earnings data on Thursday, October 26th. The medical equipment provider reported $0.31 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $0.31. Boston Scientific had a return on equity of 23.60% and a net margin of 9.55%. The company had revenue of $2.22 billion for the quarter, compared to analyst estimates of $2.21 billion. During the same period in the previous year, the company posted $0.27 EPS. The firm’s revenue for the quarter was up 5.6% compared to the same quarter last year. equities analysts forecast that Boston Scientific will post 1.25 EPS for the current fiscal year.

Several brokerages have issued reports on BSX. BMO Capital Markets restated a “buy” rating and issued a $32.00 target price on shares of Boston Scientific in a research note on Tuesday, December 12th. TheStreet lowered Boston Scientific from a “b” rating to a “c+” rating in a research note on Thursday, December 7th. Needham & Company LLC upgraded Boston Scientific from a “buy” rating to a “strong-buy” rating and boosted their target price for the company from $25.04 to $32.00 in a research note on Friday, December 8th. SunTrust Banks set a $33.00 target price on Boston Scientific and gave the company a “buy” rating in a research note on Monday, December 4th. Finally, Cowen set a $31.00 target price on Boston Scientific and gave the company a “buy” rating in a research note on Thursday, November 30th. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating, fourteen have given a buy rating and one has issued a strong buy rating to the company’s stock. The company currently has an average rating of “Buy” and a consensus target price of $31.03.

In other Boston Scientific news, EVP Timothy A. Pratt sold 11,061 shares of the company’s stock in a transaction dated Monday, October 2nd. The stock was sold at an average price of $29.24, for a total value of $323,423.64. Following the transaction, the executive vice president now directly owns 174,681 shares in the company, valued at approximately $5,107,672.44. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Valley Gold Master Fund L. Sun bought 408,006 shares of the firm’s stock in a transaction on Tuesday, November 28th. The stock was acquired at an average price of $0.45 per share, for a total transaction of $183,602.70. Over the last quarter, insiders have sold 424,698 shares of company stock worth $12,273,553. 0.74% of the stock is currently owned by corporate insiders.

COPYRIGHT VIOLATION NOTICE: “Boston Scientific (BSX) Earns Coverage Optimism Score of 0.21” was reported by Watch List News and is owned by of Watch List News. If you are reading this news story on another domain, it was copied illegally and republished in violation of U.S. & international copyright & trademark law. The original version of this news story can be read at https://www.watchlistnews.com/boston-scientific-bsx-earns-coverage-optimism-score-of-0-21/1773314.html.

Boston Scientific Company Profile

Boston Scientific Corporation is a developer, manufacturer and marketer of medical devices that are used in a range of interventional medical specialties. The Company offers its products by seven businesses: Interventional Cardiology, Cardiac Rhythm Management, Endoscopy, Peripheral Interventions, Urology and Pelvic Health, Neuromodulation, and Electrophysiology.

Insider Buying and Selling by Quarter for Boston Scientific (NYSE:BSX)

Receive News & Ratings for Boston Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Boston Scientific and related companies with MarketBeat.com's FREE daily email newsletter.